

Intensity (counts)
12000
10000
8000
6000
4000
2000
0
5
10
15
20
25
30
2Theta (°)

FIG. 1



Treatment day 16-37
Vehicle (20% HP-β-CD)
CompoundA3_30 mg/kg/QD
CompoundA3_100 mg/kg/QD
Mean Tumor Volume +/- SEM (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
40
Days Post Tumor Implant

FIG. 2




Treatment day 3-30
Vehicle (20% HP-β-CD)
Compound A3 _30mg/kg/QD
Compound A3 _50mg/kg/QD
Compound A3 _100mg/kg/QD
Percent survival
100
50
0
0
20
40
60
80
100
120
Days Post Tumor Inoculation

FIG. 3

A


100
80
60
40
20
0
Percent Survival
0
10
20
30
40
50
Compound A1
azacitidine
Days Post Tumor Engraftment
vehicle control
azacitidine 2 mg/kg
Compound A1 30 mg/kg
Compound A1 + azacitidine
*
* *

B



100
80
60
40
20
0
Percent Survival
0
10
20
30
40
50
Compound A1
azacitidine
Days Post Tumor Engraftment
vehicle control
azacitidine 2 mg/kg
Compound A1 10 mg/kg
Compound A1 + azacitidine
**
*

FIG. 4




Treatment Day 5-32
Vehicle control
Compound A1 (10 mg/kg)
Gilteritinib (10 mg/kg)
Gilteritinib (10 mg/kg) + Compound A1 (10 mg/kg)
Percentage Survival(%)
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
25
30
35
40
45
Days Post Tumor Inoculation

FIG. 5

A


MOLM-13
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
Compound A4
1e-01
1e+00
1e-01
5e-02
1e-02
1e-03
5e-04
5e-03
1e-02
1e-01
1e+00
Gilteritinib (μM)
≤0.001
0.01
0.05
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.1
0.05
0.01
≤0.001

B




MV4-11
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
Compound A4
1.000
0.500
0.100
0.050
0.010
0.001
5e-04
5e-03
1e-02
5e-02
1e-01
1e+00
Gilteritinib (μM)
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001

FIG. 6

A


MOLM-13
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
Midostaurin (μM)
0.5000
0.1000
0.0500
0.0250
0.0060
0.0012
1e-03
1e-02
5e-02
1e-01
1e+00
1e+01
Compound A4 (μM)
≤0.001
0.01
0.03
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.1
0.05
0.01
≤0.001

B




MV4-11
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
Midostaurin (μM)
0.5000
0.1000
0.0500
0.0250
0.0060
0.0012
1e-03
1e-02
5e-02
1e-01
1e+00
1e+01
Compound A4 (μM)
≤0.001
0.01
0.05
0.01
≤0.001

FIG. 7

A


MOLM-13
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
Compound A4 (μM)
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
0.0005
0.0010
0.0025
0.0050
0.0500
0.5000
Idarubicin (μM)

B



OCI-AML3
(NPM1c)
Contour plot for maxR
p-values
Compound A4 (μM)
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
5e-04
5e-03
5e-02
5e-01
1e+00
Idarubicin (μM)

FIG. 8



MOLM-13
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001
Compound A4
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
0.0015
0.0150
0.1500
1.5000
3.0000
Decitabine (μM)

FIG. 9A



OCI-AML3
(NPM1c)
Contour plot for maxR
p-values
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001
Compound A4
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
0.0015
0.0150
0.1500
1.5000
3.0000
Decitabine (μM)

FIG. 9B



Contour plot for maxR
p-values
≤0.001
0.01
0.05
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.1
0.05
0.01
≤0.001
Compound A3 (μM)
1
0.25
0.0625
0.0156
0.004
0.001
Compound 22 (nM)
0.0997
0.309
0.927
2.79
8.37
25
75

FIG. 10A



Contour plot for maxR
p-values
≤0.001
0.01
0.05
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.1
0.05
0.01
≤0.001
Compound A3 (μM)
15
3.75
0.937
0.240
0.059
0.015
Compound 22 (nM)
0.06
0.24
0.98
3.99
15.6
62.4
250

FIG. 10B



Treatment Day 5-32
Vehicles
Compound 22 (0.063 mg/kg)
Compound 22 (0.125 mg/kg)
Compound A1 (10 mg/kg)
Compound A1 (30 mg/kg)
Compound 22 (0.063 mg/kg)+ Compound A1(10 mg/kg)
Compound 22 (0.063 mg/kg)+ Compound A1(30 mg/kg)
Compound 22 (0.125 mg/kg)+ Compound A1 (10 mg/kg)
Compound 22 (0.125 mg/kg)+ Compound A1 (30 mg/kg)
Percentage Survival(%)
0
10
20
30
40
50
60
70
80
90
100
0
20
40
60
80
100
Days Post Tumor Inoculation

FIG. 11A



Treatment Day 5-32
Vehicles
Compound 22 (0.125 mg/kg)
Compound 22 (0.25 mg/kg)
Compound A1 (30 mg/kg)
Compound A1 (100 mg/kg)
Compound 22 (0.125 mg/kg)+Compound A1 (30 mg/kg)
Compound 22 (0.25 mg/kg)+ Compond A1 (100 mg/kg)
Percentage Survival(%)
100
90
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30 35 40 45 50 55 60
Days Post Tumor Inoculation

FIG. 11B